Clinical trials on HSV Infection

Understanding HSV Infection

Herpes Simplex Virus (HSV) infection is a widespread viral disease caused by two types of viruses: HSV-1 and HSV-2. These viruses are highly contagious and can be transmitted through direct contact with an infected individual. HSV-1 is primarily associated with oral herpes, leading to cold sores or fever blisters around the mouth. On the other hand, HSV-2 is mainly responsible for genital herpes, causing sores or blisters in the genital area. However, it’s important to note that both types can cause symptoms in either location, depending on the mode of transmission.

Transmission and Symptoms

HSV is transmitted through direct contact with an infected person. This can occur during intimate contact, kissing, or sharing personal items like utensils or lip balm. Once infected, individuals may experience a range of symptoms. Initial symptoms often include pain, itching, and redness in the affected area, followed by the appearance of painful blisters or ulcers. Some individuals may also experience flu-like symptoms, such as fever, body aches, and swollen lymph nodes. It’s crucial to understand that many people infected with HSV may not show any symptoms at all, yet they can still transmit the virus to others.

Management and Prevention

While there is currently no cure for HSV infection, antiviral medications can help manage symptoms and reduce the frequency of outbreaks. These treatments can also decrease the risk of transmitting the virus to others. Preventative measures include avoiding direct contact with sores, practicing safe sex by using condoms, and not sharing personal items that may have come into contact with the virus. For those with frequent outbreaks, daily antiviral therapy may be recommended to reduce the likelihood of transmission to partners.

  • CT-EU-00053530

    Examining the Pritelivir for HSV Infection treatment

    This clinical trial focuses on evaluating the effectiveness of a new medication, pritelivir, in treating sores and infections caused by the Herpes virus in the mouth and skin. The study specifically targets individuals for whom the virus is not responsive to the standard medication acyclovir. The trial is divided into sections A to F, with parts A, B, and D already completed. The remaining parts (C, E, and F) will involve comparing pritelivir with other drugs selected by the doctor to determine which medication can heal all lesions within 28 to 42 days and which one can reduce pain and the presence of the virus in the body most rapidly.

    • Cidofovir
    • Foscarnet
    • Imiquimod
    • Pritelivir